

---

# Technical Information

---

## Kollidon® CL-M

Crospovidone excipient for the pharmaceutical industry

---

February 2025 | First version | DAWF-2025-0096

03\_250201e-00/Page 1 of 10

® = Registered trademark of BASF in many countries.

 **BASF**

We create chemistry



## Raw material and production information

Insoluble Kollidon® CL crospovidone grades are manufactured through a unique polymerization process known as “popcorn” polymerization.

This process starts with the monomer N-vinyl-pyrrolidone in an aqueous system, resulting in crosslinked insoluble polyvinylpyrrolidone particles. The crosslinking is both chemical and physical, with physical crosslinking - mainly achieved through polymer chain entanglement - dominating the product properties. Therefore, when analyzed with IR spectroscopy, insoluble crospovidone cannot be distinguished from soluble povidone (linear PVP).

Kollidon® CL-M is the only grade of Kollidon® CL where the final particles are obtained through a milling step. The particles have an irregular shape and surface, which can be observed using Scanning Electron Microscopy (Fig. 1).




Fig. 1: Scanning Electron Microscopy Pictures

## Particle Size Distribution

The particle size distribution is a crucial characteristic for Kollidon® CL-M and its various applications.

Table 1 illustrates the exemplary range for particle size distribution, determined by means of laser diffraction of the material dispersed in water (wet dispersion). The test method applied by BASF (PM02331QC) is available in RegXcellence®.

A comparison of the particles size in their dry state and after dispersion in water is shown in Fig. 3.

Table 1: Particle Size	d (0.1) [µm]	d (0.5) [µm]	d (0.9) [µm]
	< 3	2 - 8	8 - 18

## Hygroscopicity

All Kollidon® CL grades exhibit hygroscopic properties, which are essential for their primary application as disintegrants. There is hardly any difference between the individual grades so that they can all be represented by a single curve (Fig. 2). The curve shows the amount of water absorbed after seven days' exposure to different conditions of relative humidity.




Fig. 2: Hygroscopicity of the Kollidon® CL-M

## Bulk and Tap Density, Flowability

The fine particles correspond to relatively low bulk and tap density for Kollidon® CL-M, which is not free flowing.

Table 2:	Bulk Density [g/l]	Tap Density [g/l]
	0.15 - 0.27	0.25 - 0.35

## 3. Functionality related Characteristics

### Swelling and Hydration Properties

The swelling behavior of crospovidone is crucial and can be described by its water adsorption or hydration capacity, as shown in Table 3. Kollidon® CL-M swells without forming a gel, although its absolute swelling is less pronounced compared to other crospovidone grades.

The sedimentation of Kollidon® CL-M suspended in water is very slow, as indicated by the settling volume test.

Table 3:	Hydration capacity [g water/g polymer]	Settling volume [ml]
	3.0 - 4.5	> 60

*Test for Hydration Capacity and Settling Volume are conducted according to Ph.Eur. Monograph Crospovidone*

The swelling of the material can be tested by comparing the particles size in their dry state and after dispersion in water. Figure 3 shows the increase of the particle size corresponding to the water uptake with one example batch of Kollidon® CL-M, measured by laser diffraction.




Fig. 3: Comparison of particle size distribution of Kollidon® CL-M: dry and wet, after dispersion in water (Qualitative example). The measurements have been carried out on Malvern Mastersizer 2000, 2.0 bar.

#### 4. Example Application(s)

Kollidon® CL-M's unique properties make it a versatile excipient used in various and diverse pharmaceutical applications, as summarized in Table 4.

Table 4: Main applications of Kollidon® CL-M	
Disintegrant	Swelling without gel formation
Dry binder	Good dry binding properties combining very fine particles with good compactability
Coating	The micronized particles can be used in tablet coatings, offering an alternative to white pigments, such as titanium dioxide (TiO <sub>2</sub> ) or talcum.
Complex formation	Selective adsorption of substances like polyphenols and certain endotoxins through complex formation
Stabilizer	Acts as a stabilizer for water-sensitive compounds, such as in vitamin formulations, due to its hygroscopicity and ability to absorb water
Suspension stabilizers	Low settling tendency of dispersed hydrophilic micronized particles helps physically stabilize oral and topical suspensions

#### Disintegrant and Dry Binding Properties

While not a super disintegrant, Kollidon® CL-M's dual functionality as both a disintegrant and an effective dry binder makes it a unique bi-functional excipient, often termed a 'binding disintegrant'.

The example below demonstrates the bi-functionality of Kollidon® CL-M in placebo tablets (Table 5) obtained through direct compression of Ludipress® LCE, a co-processed excipient consisting of lactose monohydrate and Kollidon® 30 (Povidone).

**Table 5: Tablets composition [g/100g]**

	<b>Kollidon® CL-M</b>	<b>No disintegrant</b>
Kollidon® CL-M	5.0	-
Ludipress® LCE	94.5	99.5
Magnesium Stearate	0.5	0.5


*Ludipress® LCE is mixed with Kollidon® CL-M in a turbula mixer, followed by the addition of the lubricant magnesium stearate*

Round-shaped tablets are prepared applying compression forces of 5, 7.5, 10, 12.5, and 15 kN, respectively. For comparison, formulations with and without Kollidon® CL-M have been tested.

Tablets with Kollidon® CL-M clearly show faster disintegration than the corresponding tablets without disintegrant, especially when higher compression forces were applied (Table 6).

**Table 6: Disintegration of tablets [min]**

<b>Compression force [kN]</b>	<b>Kollidon® CL-M</b>	<b>No disintegrant</b>
5	~ 3.5	~ 3
7.5	~ 4	~ 5
10	~ 4	~ 6.5
12.5	~ 5	~ 8.5
15	~ 5	~ 9



*Fig. 4: Tensile strength of tablets as function of compression pressure: comparison with and without Kollidon® CL-M (Korsch XP1 single punch press; round shape tablets: 12 mm diameter 300mg weight)*

The tensile strength plot demonstrates the dry binding effect that is observed when Kollidon® CL-M is used in the formulations of the tablets (Fig. 4). Beside direct compression, Kollidon® CL-M contributes as dry-binder in roll compaction applications, too.

### Coating tablet cores containing Kollidon® CL-M

When tablet cores containing a high amount of Kollidon® CL-M are sugar or film coated, it is important to carefully select suitable coating parameters and equipment due to crospovidone's tendency to absorb water and swell. This is particularly crucial if water is used as the solvent for the coating process.

In such cases, it is recommended to increase the drying efficiency during the process or use a polymer dissolved in an organic solvent as a sub-coating layer. A 10% solution of Kollidon® VA 64 in isopropanol, ethanol, or ethyl acetate provides an effective sub-coating. This solution can be sprayed onto the prewarmed tablet cores in the same coating pan before applying the aqueous coating (see Technical Information, "Kollidon® VA 64").

### Complex Formation

Like soluble Kollidon® grades and other Kollidon® CL grades, Kollidon® CL-M forms chemical complexes or associates with a wide range of drugs and other substances. The formation of these complexes is reversible and no complex formation occurs in alkaline medium. Whether crospovidone in general forms a complex with an API depends significantly on the API's chemical structure. Systematic investigations have shown that complexes are more readily formed with aromatic compounds that contain phenyl and/or carboxyl groups. For several APIs that form complexes with Kollidon® CL-M, accelerated dissolution rates have been observed. The ability to form complexes has many uses in pharmaceuticals, such as:

- improving the dissolution and bioavailability of drugs
- adsorbing and removing polyphenols and tannins from tinctures and herbal extracts
- improving the taste of azithromycin, paracetamol and vitamins

### Stabilization of Vitamins

The stabilizing effect of Kollidon® CL-M is demonstrated using a multivitamin liquid suspension as example. As shown in Table 7, the accelerated storage test of the vitamins (vitamin B1, calcium pantothenate and vitamin C) in the formulation prepared with Kollidon® CL-M presented better results than the one without it, highlighting the stabilizing property of this crospovidone grade.

**Table 7: Vitamin degradation in multivitamin instant drink with and without Kollidon® CL-M (30°C / 79% relative humidity)**

Storage Time [months]	1	2	3	5
Vitamin B1:				
Without Kollidon® CL-M	4%	11%	16%	26%
With Kollidon® CL-M	0%	1%	7%	10%
Vitamin C:				
Without Kollidon® CL-M	17%	18%	40%	49%
With Kollidon® CL-M	0%	2%	13%	19%
Ca-Pantothenate:				
Without Kollidon® CL-M	-	8%	21%	50%
With Kollidon® CL-M	-	10%	10%	15%

## Stabilization of suspensions

Kollidon® CL-M hydrophilic particles can be used in concentrations of 5 – 12% to physically stabilize oral and topical suspensions.

The stabilizing effect is achieved as the swollen particles increase the volume of the sediment, leading to a reduced sedimentation rate and an improved re-dispersion ability of the sediment upon shaking (anticaking effect). Importantly, Kollidon® CL-M does thereby not increase the viscosity of the preparation.

As suspension stabilizers, Kollidon® CL-M can be applied into readily formulated suspensions as well as into powder dosage forms for suspension preparation.

The increase in sediment volume achieved with Kollidon® CL-M in such suspensions can be further enhanced by adding auxiliaries such as sodium citrate (as an electrolyte), sugars, or one of the soluble grades of Kollidon® such as Kollidon® 90 Evo. Kollidon® CL-M can also stabilize suspensions in lipophilic media such as liquid paraffin.

Table 8 presents a standard antibiotic powder formulation for suspension preparation, including Kollidon® CL-M. Citric acid is included to ensure a pH value of 4.9, which is necessary for the stability of the active ingredients, ampicillin and amoxicillin trihydrate.

The sedimentation rate is very slow, and the suspension remains readily re-dispersible for several weeks.

<b>Table 8: Example of a standard antibiotic powder for suspension formulation</b>	<b>Quantity [g]</b>	<b>Percentage [g/100g]</b>
Ampicillin or amoxicillin trihydrate	5.0	7.6
Sodium citrate	5.0	7.6
Citric acid	2.1	3.2
Sodium gluconate	5.0	7.6
Sorbitol	40.0	61.1
Kollidon® CL-M	6.0	9.2
Orange flavouring	1.5	2.3
Lime flavouring	0.5	0.8
Saccharin sodium	0.4	0.6

*Reconstitution procedure: dissolve 66 g of the final powder for suspension with purified water to obtain a final volume of 100 mL. Shake well. Final concentration: 250 mg of API per 5 mL of suspension.*

## White pigment for coating

Kollidon® CL-M can be used for tablets coating, substituting white pigments such as titanium dioxide (TiO<sub>2</sub>) and/or talcum.

The major benefits of Kollidon® CL-M for such applications include its high opacity, low sedimentation rate, and low tendency to form aggregates. These properties make the polymer suitable for this application, offering a simple preparation procedure and high process reliability.

Additionally, Kollidon® CL-M can be combined with all pigments.

Table 9 describes an application example where Kollidon® CL-M is used as white pigment in coating formulation based on the immediate release coating polymer Kollicoat® IR. For the formulation, Kollidon® CL-M is poured in water while stirring (no high-shear mixer required). Kollicoat® IR is then slowly added for avoiding lump formation, and the mixture stirred for 30 minutes.

Table 9: Example formulation for white coating	Content [g/100g]
Kollidon® CL-M	10
Kollicoat® IR	10
Water	80

## 5. Handling & safety instructions

The primary packaging of Kollidon® CL-M is a PE/EVOH liner with excellent oxygen barrier properties and is heat-sealed for proper closure. The secondary packaging is a HDPE plastic drum.

Please refer to the individual material safety data sheet (MSDS) for instructions on safe and proper handling and disposal. Material safety data sheets are sent with every consignment.

## 6. Handling & safety instructions

The product is typically stable for 36 months after date of production provided storage under recommended conditions. The actual retest period and storage conditions can be found in RegXcellence®.

The actual version of the safety data sheet is accessible via MyProductWorld and sent with every consignment.

## 7. Articles and Packaging

PRD-No.*	Product name	Article numbers	Packaging Type and Size
30444355	Kollidon® CL-M	51928647	Plastic drum 30kg
		50348144	Plastic pail 0.25kg

\* BASF's commercial product number.

## 8. Documents, Quality & Regulatory Information

Visit our BASF website to learn about the benefits of Kollidon® CL-M:

Access product documentation anytime via the BASF Virtual Pharma assistants: [Virtual Pharma Assistants](#)



Meet your Virtual Pharma Assistants! MyProductWorld, RegXcellence® and ZoomLab™

[www.virtualpharmaassistants.com](http://www.virtualpharmaassistants.com)

[MyProductWorld](#): article numbers, sample order, safety data sheet, sustainability information

[RegXcellence®](#) specification, compliance documents, regulatory product summary

[ZoomLab](#): formulation assistance to predict starting formulations and expedite drug development.

---

## Disclaimer

This document and any information provided herein does not constitute a legally binding obligation of BASF and has been prepared in good faith and is believed to be accurate as of the date of issuance. Unless expressly agreed otherwise in writing in a supply contract or other written agreement between you and BASF:

- a) To the fullest extent not prohibited by the applicable laws, BASF EXPRESSLY DISCLAIMS ALL REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, BY FACT OR LAW, INCLUDING ANY IMPLIED WARRANTIES, REPRESENTATIONS OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SATISFACTORY QUALITY, NON-INFRINGEMENT, AND ANY REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES, ARISING FROM STATUTE, COURSE OF DEALING OR USAGE OF TRADE AND BASF HEREBY EXPRESSLY EXCLUDES AND DISCLAIMS ANY LIABILITY RESULTING FROM OR IN CONNECTION WITH THIS DOCUMENT OR ANY INFORMATION PROVIDED HEREIN, including, without limitation, any liability for any direct, consequential, special, or punitive damages relating to or arising therefrom, except in cases of (i) death or personal injury, (ii) BASF's or its agents and assistants willful misconduct, fraud or fraudulent misrepresentation or (iii) any matter in respect of which it would be unlawful for BASF to exclude or restrict liability under the applicable laws;
- b) Any information provided herein can be changed at BASF's sole discretion anytime and neither this document nor the information provided herein may be relied upon to satisfy any obligations you may have to undertake your own inspections and evaluation;
- c) BASF rejects any obligation to, and will not, automatically update this document and any information provided herein, unless required by applicable law; and
- d) You are responsible for confirming that you have retrieved the most current version of this document from BASF.

February 2025